J&J earnings set ‘negative tone’; Shkreli vs. the FTC

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 14 Oct, 13:31 UTC

A 6% sell-off in J&J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is collaborating with Vir and a biotech’s bid for a product expansion fell short.

businessscience

Sources

• T2J&J earnings set ‘negative tone’; Shkreli vs. the FTCBioPharma Dive / Healthcare Dive / MedTech Dive14 Oct, 13:31